Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Secondary Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Secondary Neoplasm

Cancer Family

Secondary Neoplasm

CI-CAN-00000050Explore in graph →

Non-malignant4,276 active trials56 approved drugs532 evidence items

NCIt: C36255

Overview
Statistics
Survival
Genomics199
Variants & evidence532
Drugs130
Trials14673
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 126–150 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma.
· Mol Cancer · 2015 · PMID 26634247 · validated civic_curation pubmed
HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas.
· J Clin Invest · 2013 · PMID 23635773 · validated civic_curation pubmed
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
· Oncotarget · 2016 · PMID 26894380 · validated civic_curation pubmed
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
· Oncotarget · 2016 · PMID 26921265 · validated civic_curation pubmed
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
· J Thorac Oncol · 2011 · PMID 21847063 · validated civic_curation pubmed
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
· Oncotarget · 2016 · PMID 27086918 · validated civic_curation pubmed
Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma.
· Oncotarget · 2016 · PMID 27092876

Showing 126–150 of 486 publications

← Previous
1
…
5
6
7
…
20
Next →

· validated civic_curation

The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.

· Clin Cancer Res · 2001 · PMID 11751510 · validated civic_curation pubmed

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

· J Clin Oncol · 2009 · PMID 19667267 · validated civic_curation pubmed

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

· J Clin Oncol · 2010 · PMID 20368568 · validated civic_curation pubmed

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

· Am J Pathol · 2010 · PMID 20813970 · validated civic_curation pubmed

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

· Clin Cancer Res · 2013 · PMID 23470965 · validated civic_curation pubmed

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

· J Clin Oncol · 2013 · PMID 23382472 · validated civic_curation pubmed

Toward the molecular dissection of peritoneal pseudomyxoma.

· Ann Oncol · 2016 · PMID 27502722 · validated civic_curation pubmed

Genetic Variants in the p14ARF/MDM2/TP53 Pathway Are Associated with the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated with Radical Resection.

· PLoS One · 2016 · PMID 27414035 · validated civic_curation pubmed

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.

· J Ovarian Res · 2016 · PMID 27209210 · validated civic_curation pubmed

Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma.

· BMC Cancer · 2015 · PMID 25924824 · validated civic_curation pubmed

Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma.

· Oncotarget · 2016 · PMID 27304188 · validated civic_curation pubmed

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

· J Clin Oncol · 2015 · PMID 25847936 · validated civic_curation pubmed

Mutational landscape of aggressive cutaneous squamous cell carcinoma.

· Clin Cancer Res · 2014 · PMID 25303977 · validated civic_curation pubmed

Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma.

· BMC Cancer · 2015 · PMID 26674738 · validated civic_curation pubmed

Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.

· JAMA · 2010 · PMID 21177507 · validated civic_curation pubmed

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

· Lancet Oncol · 2011 · PMID 21862407 · validated civic_curation pubmed

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

· Lancet Oncol · 2015 · PMID 26051236 · validated civic_curation pubmed

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

· Ann Oncol · 2015 · PMID 25899785 · validated civic_curation pubmed